A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (D-Beyond)

Dataset ID Technology Samples
EGAD00001004391 Illumina NovaSeq 6000 72

Dataset Description

This is a prospective, single arm phase IIa trial in which patients with early breast cancer will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart (maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be collected at baseline and at surgery. Post-operative treatment will be at the discretion of the investigator.Primary objective: to determine if a short course of RANKL inhibition with denosumab can induce a decrease in tumor proliferation rates as determined by Ki67 immunohistochemistry (IHC) in newly diagnosed, early stage breast cancer in pre-menopausal women.

Who controls access to this dataset

For each dataset that requires controlled access, there is a corresponding Data Access Committee (DAC) who determine access permissions. Access to actual data files is not managed by the EGA. If you need to request access to this data set, please contact:

Institut Jules Bordet Data Access Committee for EGAS00001002685 study
Contact person: David Venet
Email: david [dot] venet [at] bordet [dot] be
More details: EGAC00001000748


You don't have access to the download section.